InsidersTradesSigma
Track the Electromed, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Electromed, Inc. has published 77 public disclosures. Market capitalisation: €247.6m. The latest transaction was disclosed on 3 September 2026 (Retenue fiscale). Among the most active insiders: SKARVAN KATHLEEN. The full history is openly available.
77
Insider Decl.
n/a
Thresholds
€600,042
8 ops.
Buy Volume
€3m
11 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Electromed, Inc. Strong Buy (bullish), based on 3 analysts. Average price target: US$45.67.
54Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 5,024 of 29,063 companies
68.5
score / 100
Value51
Quality86
FCF yld3.4%
Earn yld4.6%
EV/EBITDA16.6x
ROE23%
Gross mgn79%
Net mgn15%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 September 2026
Declarations77 total
2,671 shares@ US$27.10Common StockSEC:0001437749-26-029617:0
4,900 shares0Common StockSEC:0001437749-26-029618:0
1,102 shares@ US$27.10Common StockSEC:0001437749-26-029618:1
9,700 sharesCommon StockSEC:0001437749-26-020030:0
7,003 sharesCommon StockSEC:0001437749-26-020030:1
1,671 sharesCommon StockSEC:0001437749-26-020030:2
1,026 sharesCommon StockSEC:0001437749-26-020030:3
9,700 shares@ US$36.50470.092% mcap65.3% of flowCommonSEC144:0001959173-26-004418
4,334 shares@ US$10.250.012% mcap8.4% of flowCommon StockSEC:0001437749-26-019883:0
5,267 shares@ US$10.710.016% mcap10.6% of flowCommon StockSEC:0001437749-26-019883:1
11,620 shares@ US$36.33550.12% mcap79.7% of flowCommon StockSEC:0001437749-26-019883:2
181 shares@ US$37.1140.0019% mcap1.3% of flowCommon StockSEC:0001437749-26-019883:3
11,801 shares@ US$36.34750.11% mcap44.1% of flowCommonSEC144:0001959173-26-004359
3,000 shares0Common StockSEC:0001437749-25-036837:0
3,000 shares0Common StockSEC:0001437749-25-036834:0
3,000 shares0Common StockSEC:0001437749-25-036833:0
3,000 shares0Common StockSEC:0001437749-25-036832:0
3,000 shares0Common StockSEC:0001437749-25-036831:0
3,000 shares0Common StockSEC:0001437749-25-036829:0
3,000 shares0Common StockSEC:0001437749-25-036828:0
39,378 shares@ US$23.679136.2% of flowCommon StockSEC:0001437749-25-028940:0
1,291 shares@ US$23.9516.3% of flowCommon StockSEC:0001437749-25-028374:0
562 shares@ US$23.952.5% of flowCommon StockSEC:0001437749-25-028373:0
15,689 shares@ US$28.7130.7% of flowCommon StockSEC:0001437749-25-004964:0
40,000 shares@ US$1.804.8% of flowCommon StockSEC:0001437749-25-004433:0
25 of 77 declarations
关于 Electromed, Inc.
Electromed, Inc. (股票代码: ELMD) 是一家在美国纽约证券交易所美国市场上市的美国医疗设备公司，具有专注的中小型市值特征。公司总部位于明尼苏达州新布拉格，成立于1992年，其业务围绕肺功能受损患者的气道清除疗法。Electromed 开发、制造、销售和支持基于高频胸壁振荡 (HFCWO) 的产品，这是一种旨在帮助动员和清除气道粘液的疗法。([sec.gov](https://www.sec.gov/Archives/edgar/data/1488917/000089710124000486/elmd241000_ars.pdf?utm_source=openai)) 其核心商业平台是 SmartVest 系列，包括最新的 SmartVest Clearway 系统、早期的 SmartVest SQL 以及相关的服装和配件。这些产品用于支气管扩张、囊性纤维化以及某些神经肌肉或慢性呼吸系统疾病等病症。重要的是，Electromed 不仅仅是一家设备供应商：它运营着一种服务密集型模式，包括患者和临床医生教育、治疗培训、后续支持、报销协助以及持续的参与，以帮助将治疗融入日常护理。在报销、依从性和临床支持严重影响采用的利基市场中，这种服务层具有战略重要性。([sec.gov](https://www.sec.gov/Archives/edgar/data/1488917/000143774925034445/elmd20250930_10q.htm?utm_source=openai)) 从竞争角度来看，Electromed 是一家专业公司，而非多元化的医疗技术集团。管理层始终将公司定位为气道清除领域的领导者，这得益于临床结果数据、既定的报销途径以及直接面向患者/供应商的市场推广方法。该业务绝大多数以美国为中心：大部分收入来自国内，而国际销售仍然微薄。制造也设在明尼苏达州，这表明其运营模式相对整合，对产品质量和供应链执行有更严格的控制。([sec.gov](https://www.sec.gov/Archives/edgar/data/0001488917/000143774926016422/ex_920786.htm?utm_source=openai)) 公司近期沟通强调持续增长、盈利能力和商业投资。管理层强调销售团队扩张、客户关系管理和资本支出、市场开发举措以及股票回购，而投资者演示文稿则继续将公司定位为一家不断增长且盈利的医疗技术企业。对于关注 SEC Form 4 内部人交易的投资者而言，ELMD 也值得关注，因为内部人交易受到密切关注，可能反映与薪酬相关的授予、例行出售或更广泛的管理层一致性。总体而言，Electromed 仍然是一个专注于呼吸护理的利基医疗保健公司，其商业化、报销以及家庭气道清除需求扩张的执行是关键的投资驱动因素。([sec.gov](https://www.sec.gov/Archives/edgar/data/1488917/000143774925034438/ex_859448.htm?utm_source=openai))
